RecruitingPhase 2NCT07211685
BAY3401016; Biomarker Study Alport
Studying Alport syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bayer
- Intervention
- BAY 3401016(biological)
- Enrollment
- 60 enrolled
- Eligibility
- 18-45 years · All sexes
- Timeline
- 2025 – 2028
Study locations (30)
- Nephrology Clinic at The Kirklin Clinic of UAB Hospital, Birmingham, Alabama, United States
- The Peggy and Harold Katz Family Drug Discovery Center - Nephrology, Miami, Florida, United States
- Center for Advanced Pediatrics - Nephrology, Atlanta, Georgia, United States
- Cardio Renal Institute, Chubbuck, Idaho, United States
- Tufts Medical Center | Nephrology Department, Boston, Massachusetts, United States
- Renal Disease Research Institute | Landry, Dallas, Texas, United States
- Hospital Británico, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
- Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC), Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
- Centro de Rehabilitacion Cardiovascular | San Luis, Argentina, San Luis, San Luis Province, Argentina
- Clinica de Nefrologia, Urologia y Enfermedades Cardiovasculares S.A., Santa Fe, Argentina
- St. Joseph's Healthcare - Hamilton, Hamilton, Ontario, Canada
- London Health Sciences Centre (LHSC) - University Hospital, London, Ontario, Canada
- Lakeridge Health-Oshawa, Oshawa, Ontario, Canada
- McGill University Health Centre - Glen Site, Montreal, Quebec, Canada
- CHU de Québec-Université Laval, Québec, Quebec, Canada
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07211685 on ClinicalTrials.govOther trials for Alport syndrome
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE4NCT06499948Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients with Alport Syndrome (COMBINE-ALPORT)Stefan Lujinschi
- ACTIVE NOT RECRUITINGNCT06226896Effects of Dapagliflozin on Progression of Alport SyndromeNanjing University School of Medicine
- RECRUITINGNCT06526741ASF Alport Patient RegistryAlport Syndrome Foundation
- ACTIVE NOT RECRUITINGPHASE2NCT04573920Atrasentan in Patients With Proteinuric Glomerular DiseasesNovartis Pharmaceuticals
- RECRUITINGNCT04947813Genotype-Phenotype Correlations in Patients With Alport SyndromeXinhua Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGNCT05927467Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)Institut National de la Santé Et de la Recherche Médicale, France
- RECRUITINGNCT02378805Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport SyndromeUniversity Hospital Goettingen